Fan Jin

发表

1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM).

A. Hauschild, C. Blank, V. Chiarion Sileni, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.